Peptides for beta-cell survival and insulin production
A method to prevent a disease, comprising: (1) administering a peptide comprising Delta6PV into a subject comprising a human or an animal; wherein the disease comprises one of more of Type 1 diabetes, rheumatoid arthritis, lupus, Sjogren's syndrome, multiple sclerosis, Graves' disease, giant cell arteritis, ankylosing spondylitis, and Guillain Barre Syndrome; and (2) monitoring the disease in the subject.
1 . A method to delay onset of a disease, comprising: taking a composition comprising Delta6PV, and administering an effective amount of the composition into a subject, wherein the disease comprises type 1 diabetes, wherein the subject is a human or an animal, wherein the Delta6PV in the subject:
(a) delays onset of infiltration of immune cells into islets;
(b) does not impair T cell cytotoxicity; and
(c) inhibits IL-2 driven expansion of primary T cells.
2 . The method of claim 1 , wherein the Delta6PV inhibits IL-7, and/or IL-15 driven expansion of primary T cells in the subject.
3 . The method of claim 1 , wherein the Delta6PV inhibits primary CD8+ T cell expansion in the subject.
4 . The method of claim 1 , wherein the Delta6PV does not impair antigen-specific cytotoxicity by T cells in the subject.
5 . The method of claim 1 , wherein Delta6PV does not impair naïve T cell activation.
6 . The method of claim 1 , wherein Delta6PV increases islet insulin content in the subject.
7 . The method of claim 1 , wherein the Delta6PV inhibits IL-7 driven expansion of primary T cells in the subject.
8 . The method of claim 1 , wherein the Delta6PV inhibits IL-15 driven expansion of primary T cells in the subject.
9 . The method of claim 1 , wherein the composition further comprises at least one pharmaceutical acceptable carrier.
10 . The method of claim 1 , wherein the composition optionally includes adjuvant.
11 . A method to treat a disease, comprising: taking a composition comprising Delta6PV, and administering an effective amount of the composition into a subject, wherein the disease comprises type 1 diabetes, wherein the Delta6PV in the subject inhibits IL-2 driven expansion of primary human T cells, and wherein the subject is a human or an animal.
12 . The method of claim 11 , wherein the Delta6PV inhibits IL-7, and/or IL-15 driven expansion of primary T cells in the subject.
13 . Method of claim 11 , wherein the Delta6PV inhibits primary CD8+ T cell expansion in the subject.
14 . The method of claim 11 , wherein the Delta6PV impairs antigen-specific cytotoxicity by T cells in the subject.
15 . The method of claim 11 , wherein the Delta6PV increases islet insulin content in the subject.
16 . The method of claim 1 , wherein Delta6PV does not impair naïve T cell activation.
17 . The method of claim 11 , wherein the Delta6PV inhibits IL-7 driven expansion of primary T cells in the subject.
18 . The method of claim 11 , wherein the Delta6PV inhibits IL-15 driven expansion of primary T cells in the subject.
19 . The method of claim 11 , wherein the composition further comprises at least one pharmaceutical acceptable carrier.